Pfizer just struck an $11 billion deal, and it marks an ambitious shift in the US drug giant’s blockbuster cancer strategy
|06/17/2019||Posted by BusinessMediaguide.Com under General World News||
- US drug giant Pfizer just announced that it is buying cancer biotech Array BioPharma for about $11 billion.
- Pfizer has been betting heavily that new cancer drugs will be key to its future growth.
- The latest deal marks a shift for the company into two new, important areas: the skin cancer melanoma and colorectal cancers that start in the colon or rectum.
- Click here for more BI Prime stories.
US drug giant Pfizer, which has been charting an expansion into cancer, just struck a deal to buy cancer biotech Array BioPharma for roughly $11 billion.
The deal, Pfizer’s biggest read more >>>